- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00601679
Improvement of Patients With Chronic Heart Failure Using NT-proBNP (EXIMPROVECHF)
Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study
This will be a multicentre Phase IV study in which patients with chronic HF who are managed and followed by HF/heart functions clinics will be followed over a period of two years.
Clinic patients who are recruited into the study will have obligatory blood sampling for the surveillance measurement of NT-proBNP level every three months for a minimum of one year (4 samples). One-half of the subjects in each clinic will be randomized to have these NT-proBNP values made known to the attending clinic physicians and nurses, the other half will have these values blinded. During the study, attending clinic physicians can order open-label NT-proBNP or BNP assays, if available in their institution, to assist the management of their patients if they feel it is clinically needed.
Studieöversikt
Detaljerad beskrivning
Once an eligible clinic patient is identified, written informed consent will be obtained. All patients will have blood drawn for the measurement of NT-proBNP immediately after consent is obtained. The patient will then be randomized to either the usual care or NT-proBNP arm.
For each patient enrolled into the study the attending physician will ensure obligatory blood sampling for the measurement of NT-proBNP level every three months for a minimum of one year (4 samples). Conventional measures used in programmed management settings including history taking, physical and radiographic examination and echocardiography will also be undertaken as per clinical practice. Patients from both arms will be treated with the same conventional measures.
One-half of the subjects in each clinic will be randomized to have these NT-proBNP values made known to the attending clinic physicians and nurse practitioners. The other half (Usual Care) will have these values blinded. During the study, attending clinic physicians can order NT-proBNP or BNP assays, if available in their institution, to assist the management of their patients if they feel it is clinically needed. Demographic variables such as age, gender, BMI, serum creatinine, and eGFR will also be collected in both arms. A dedicated research coordinator based in St. Michael's Hospital, the core centre, will monitor patients, data and blood sample collection from all participating clinics. NT-proBNP will be measured on site in clinics with the facility to measure NT-proBNP. For clinics that do not have the facility, the samples will be shipped to the core centre for measurement and the results will be provided to the clinic within one week for those patients who are randomized to open-label NT-proBNP. The research coordinator, via close communications with the clinic nurses and physicians, will ensure the process is immaculately executed and blinding is maintained.
All patients will be followed every three months for a minimum of one year (4 samples) and will include an initial evaluation (Visit 1) along with four follow-up visits in the HF/heart functions clinics (Visits 2 - 5). A clinic visit will be requested for those patients having experienced a serious adverse event since Visit 1.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6Z 1Y6
- St. Paul's Hospital
-
-
Ontario
-
Toronto, Ontario, Kanada, M5B 1W8
- St Michael's Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years of age
- NYHA class II-IV heart failure
- Followed in a programmed heart failure (HF) management setting
Exclusion Criteria:
- Life expectancy <1 year due to causes other than HF such as advanced cancer
- Any other conditions that may render the patient ineligible according to the investigator's judgment
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: NT-proBNP
Surveillance NT-proBNP levels disclosed to physicians.
Intervention (e.g.
Diuretic management) based on NT-proBNP results.
|
knowledge of NT-proBNP results
|
Inget ingripande: Usual Care
Surveillance NT-proBNP levels blinded.
Intervention (e.g.
Diuretic management) based on clinical judgments.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Heart failure hospitalization and death
Tidsram: 2 years
|
2 years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Time to hospitalization/admission to ED due to HF, total number of HF events, total number of hospitalizations for cardiovascular events, all-cause mortality, cardiovascular mortality, worsening in clinical status but not requiring hospital admission
Tidsram: 2 years
|
2 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Gordon W Moe, MD, FACC, Unity Health Toronto
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CAN0013
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hjärtsvikt
-
Region SkaneAnmälan via inbjudanHjärtsvikt New York Heart Association (NYHA) klass II | Hjärtsvikt New York Heart Association (NYHA) klass IIISverige
-
Taichung Veterans General HospitalRekryteringKontinuerlig Fetal Heart Beat Monitor och analys efter Spinal AnestesiTaiwan
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... och andra samarbetspartnersHar inte rekryterat ännuHjärtsvikt, systolisk | Hjärtsvikt Med Minskad Ejection Fraktion | Hjärtsvikt New York Heart Association Klass IV | Hjärtsvikt New York Heart Association Klass IIIPolen
-
University of WashingtonAmerican Heart AssociationAvslutadHjärtsvikt, Kongestiv | Mitokondriell förändring | Hjärtsvikt New York Heart Association Klass IVFörenta staterna
-
Novartis PharmaceuticalsAvslutadPatienter som framgångsrikt slutfört den 12 månader långa behandlingsperioden i kärnstudien (de Novo Heart Recipients) som var intresserade av att bli behandlad med EC-MPS
-
University Hospital, GasthuisbergOkändTransient Left Ventricular Ballooning SyndromeBelgien
-
Children's Hospital Medical Center, CincinnatiRekryteringNationellt samarbete för att förbättra vården av barn med komplexa medfödda hjärtsjukdomar (NPC-QIC)Hypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna, Storbritannien, Kanada
-
Lifetech Scientific (Shenzhen) Co., Ltd.OkändPatent Ductus Arteriosus | Kanalberoende Cyanotic Congenital Heart DiseaseMalaysia
-
Mayo ClinicRekryteringHypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna
-
NYU Langone HealthRekryteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeFörenta staterna
Kliniska prövningar på NT-proBNP guided care
-
Mayo ClinicAvslutadGraviditetskomplikationer | Medfödd hjärtsjukdomFörenta staterna
-
Sohag UniversityHar inte rekryterat ännu
-
General Hospital Murska SobotaRoche Pharma AG; Slovenian Research Agency; Murska Sobota Municipiality; Community...OkändHjärtsviktSlovenien
-
University of ValenciaAvslutad
-
Hospital Universitario Virgen de la ArrixacaJuan Cinca Cuscullola; Pablo García Pavía; Manuel Martinez Selles; Antoni Bayés... och andra samarbetspartnersAvslutadHjärtsvikt | Bevarad vänsterkammarutkastningsfraktionSpanien
-
Washington University School of MedicineUniversity of Abuja Teaching HospitalAvslutadHypertensiv sjukdom vid graviditetNigeria
-
NHS Greater Glasgow and ClydeKarolinska University Hospital; University of British Columbia; Uppsala University och andra samarbetspartnersRekryteringHjärt-kärlsjukdomar | HjärtsviktFörenta staterna, Sverige, Kanada, Danmark, Storbritannien
-
The University of Hong KongOkänd
-
University of CataniaAvslutad
-
NHS Greater Glasgow and ClydeAstraZenecaRekryteringHjärt-kärlsjukdomar | Hjärtsvikt | Diabetes mellitus | Typ 1-diabetes | Diabetes typ 2Storbritannien